Skip to content
Open access

Estimation Of Interleukin 6 Levels And Its Correlation With Severity Of Chronic Heart Failure

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations

Abstract

Background: Chronic heart failure is associated with persistent systemic inflammation, which contributes to ventricular dysfunction and disease progression. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that may reflect the severity of myocardial impairment. Evaluating its relationship with clinical and echocardiographic parameters may help clarify its potential role as a biomarker in chronic heart failure. Aim and Objectives: To estimate serum IL-6 levels in patients with chronic heart failure and determine their correlation with disease severity, assessed using New York Heart Association (NYHA) functional class and left ventricular ejection fraction (LVEF). Results: The study included 45 patients with chronic heart failure. NYHA Classes II, III and IV comprised 21 (46.67%), 17 (37.78%) and 7 (15.56%) patients, respectively. The overall mean LVEF was 41 ± 9%. Mean LVEF declined significantly from 49 ± 7% in NYHA Class II to 35 ± 4% in Class III and 33 ± 4% in Class IV (p=0.001). NYHA class demonstrated a strong negative correlation with LVEF (r=−0.669; p=0.001). The overall mean serum IL-6 level was 16.68 ± 4.49. Mean IL-6 levels were 15.83 ± 4.04, 17.50 ± 4.62 and 17.27 ± 5.63 in NYHA Classes II, III and IV, respectively, without a statistically significant difference (p=0.254). IL-6 showed a weak, non-significant positive correlation with NYHA class (r=0.153; p=0.316). However, IL-6 demonstrated a statistically significant moderate negative correlation with LVEF (r=−0.480; p=0.001). Conclusion: Serum IL-6 was significantly associated with reduced LVEF but not with NYHA functional class. These findings suggest that IL-6 may reflect objective echocardiographic impairment more closely than symptom-based functional severity. Serum IL-6 may therefore serve as a supplementary marker of myocardial dysfunction in chronic heart failure...

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.